山西医科大学学报2026，Vol.57Issue(2)：207-214,8.DOI:10.13753/j.issn.1007-6611.2026.02.013
缺血性脑卒中患者APOE和SLCO1B1基因多态性对阿托伐他汀降脂疗效和安全性的影响
Effects of APOE and SLCO1B1 gene polymorphisms on lipid-lowering efficacy and safety of Atorvastatin in patients with ischemic stroke
摘要
Abstract
Objective To investigate the distribution of APOE and SLCO1B1 gene polymorphisms in ischemic stroke(IS)patients and their effects on the lipid-lowering efficacy and safety of Atorvastatin and the prognosis of IS patients.Methods The clinical data of IS patients who received lipid-lowering treatment with Atorvastatin,and APOE and SLCO1B1 genotyping were retrospectively collected.The associations between APOE and SLCO1B1 gene polymorphisms and the severity of IS,the risk of comorbidity occurrence,the rate of achieving lipid targets,the rates of increased liver function and creatine kinase(CK),and the risk of re-admission due to IS recurrence were analyzed.Results A total of 498 IS patients treated with Atorvastatin for lipid-lowering therapy were included in this study.The minor allele frequencies of APOE 526 and 388 loci,and SLCO1B1 388 and 521 loci were 7.43%,7.93%,28.61%,and 10.34%,respectively,and their distributions were in Hardy-Weinberg equilibrium(P>0.05).No significant differences were observed in the incidences of moderate to severe IS,hypertension,diabetes,and coronary heart disease among different genotypes,alleles,and haplotypes at each locus(P>0.05).The APOE 526 locus genotypes and diplotypes had significant effects on the target achievement rates of total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL)(P<0.05),and the 388 locus genotype significantly affected the rate of achieving TC target(P=0.017).The SLCO1B1 521 locus genotypes and diplotypes had significant effects on the rate of ALT elevation(P<0.05),and the 388 locus genotypes and diplotypes had significant effects on the rate of CK elevation(P<0.05).Multivariate Logistic regression analysis showed that gender(OR=1.80,P=0.036),age(OR=0.97,P=0.003),and comorbid hypertension(OR=2.04,P=0.047)were independent factors influencing the risk of re-admission due to IS recurrence within one year.Conclusion APOE gene polymorphisms significantly affect the lipid-lowering efficacy of Atorvastatin.SLCO1B1 gene polymorphisms significantly affect the safety of Atorvastatin.APOE and SLCO1B1 gene polymorphisms have important potential application value in the individualized treatment of IS patients.关键词
缺血性脑卒中/ApoE/SLCO1B1/基因多态性/阿托伐他汀Key words
ischemic stroke/ApoE/SLCO1B1/gene polymorphisms/Atorvastatin分类
医药卫生引用本文复制引用
刘亮,赵丹琪,王淑梅..缺血性脑卒中患者APOE和SLCO1B1基因多态性对阿托伐他汀降脂疗效和安全性的影响[J].山西医科大学学报,2026,57(2):207-214,8.基金项目
国家自然科学基金资助项目(81872926) （81872926）
